Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 5/20 | 0.49 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.49 |
| ▸ | GUSB | P08236 | 1/20 | 0.48 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16031060 | 1.00 | SGMS2 (0.57) | SGMS2SMN1; SMN2KMT2ALMNAHPGD | |
| SCHEMBL2205652 | 0.89 | SGMS2 (0.46) | SGMS2SMN1; SMN2KMT2ALMNAHPGD | |
| SCHEMBL2151279 | 0.88 | SGMS2 (0.45) | SGMS2SMN1; SMN2KMT2ALMNAHPGD | |
| SCHEMBL2207518 | 0.87 | SGMS2 (0.46) | SGMS2SMN1; SMN2KMT2ALMNAHPGD | |
| SCHEMBL2207328 | 0.87 | SGMS2 (0.46) | SGMS2SMN1; SMN2KMT2ALMNAHPGD | |
| SCHEMBL2207644 | 0.86 | FFAR1 (0.43) | SGMS2SMN1; SMN2KMT2ALMNAHPGD | |
| SCHEMBL2206995 | 0.86 | SGMS2 (0.45) | SGMS2SMN1; SMN2KMT2ALMNAHPGD | |
| SCHEMBL11099251 | 0.86 | SGMS2 (0.60) | SGMS2SMN1; SMN2KMT2ALMNAHPGD | |
| SCHEMBL2207500 | 0.84 | SGMS2 (0.40) | SGMS2LMNA | |
| SCHEMBL28029760 | 0.84 | MAOB (0.57) | SMN1; SMN2LMNAHPGDHTTNR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170022180-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2017-01-26 | — | — | US | disclosed |
| US-20160229831-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160151369-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-06-02 | — | — | US | disclosed |
| US-9133154-B2 | Substituted 3-phenylpropylamine derivatives for the treatment of ophthalmic diseases and disorders | ACUCELA INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140275043-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20080318947-A1 | Inhibitors of Akt Activity | HEERDING DIRK A | 2008-12-25 | — | — | US | disclosed |
| EP-1874768-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006113837-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275043-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, PSEN2, CLN6 | SGMS2 3022/4885SMN1; SMN2 84/4885KMT2A 1533/4885 |
| US-20160229831-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, PSEN2, CLN6 | SGMS2 3022/4885SMN1; SMN2 84/4885KMT2A 1533/4885 |
| US-20080318947-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | SGMS2 3182/4885SMN1; SMN2 3299/4885KMT2A 1852/4885 |
| US-20170022180-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, PSEN2, CLN6 | SGMS2 3022/4885SMN1; SMN2 84/4885KMT2A 1533/4885 |
| US-20160151369-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, PSEN2, CLN6 | SGMS2 3022/4885SMN1; SMN2 84/4885KMT2A 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.